Lantheus Holdings Overview
- Year Founded
-
1956
- Status
-
Public
- Employees
-
1,193
- Stock Symbol
-
LNTH
- Investments
-
12
- Share Price
-
$102.09
- (As of Friday Closing)
Lantheus Holdings General Information
Description
Lantheus Holdings Inc is a radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver patient outcomes. The Company classifies its products into Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships and Other Revenue. Its products help healthcare professionals Find, Fight and Follow cancer and diseases and are used by physicians and technologists in clinical settings. The Company produces and markets its products in the United States, mainly to hospitals, independent imaging centers and government facilities, and sells outside the United States through direct and third-party distribution relationships and licensing arrangements in Europe, Canada, Australia, Asia-Pacific, Central America and South America.
Contact Information
Website
www.lantheus.comCorporate Office
- 201 Burlington Road
- South Building
- Bedford, MA 01730
- United States
Corporate Office
- 201 Burlington Road
- South Building
- Bedford, MA 01730
- United States
Lantheus Holdings Stock Performance
As of 20-Nov-2026, Lantheus Holdings’s stock price is $102.09. Its current market cap is $6.68B with 65.4M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $102.09 | $102.10 | $53.38 - $111.86 | $6.68B | 65.4M | 1.02M | $4.14 |
Lantheus Holdings Financials Summary
As of 30-Sep-2026, Lantheus Holdings has a trailing 12-month revenue of $1.56B.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 6,530,957 | 4,650,480 | 5,972,726 | 4,247,892 |
| Revenue | 1,562,212 | 1,541,609 | 1,533,910 | 1,296,429 |
| EBITDA | 431,713 | 379,750 | 478,008 | 470,924 |
| Net Income | 269,905 | 233,559 | 312,442 | 326,661 |
| Total Assets | 2,456,133 | 2,227,399 | 1,980,340 | 1,651,149 |
| Total Debt | 624,283 | 619,432 | 619,438 | 616,946 |
Lantheus Holdings Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Lantheus Holdings Comparisons
Industry
Financing
Details
Lantheus Holdings Competitors (8)
One of Lantheus Holdings’s 8 competitors is GE HealthCare Technologies, a Corporation company based in Chicago, IL.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| GE HealthCare Technologies | Corporation | Chicago, IL | ||||
| Guerbet Group | Corporation | Villepinte, France | ||||
| Bruker | Formerly VC-backed | Billerica, MA | ||||
| Boston Scientific | Corporation | Marlborough, MA | ||||
| Bio-Rad Laboratories | Corporation | Hercules, CA |
Lantheus Holdings Patents
Lantheus Holdings Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2025213026-A1 | Astatine-211-labelled psma-binding compounds | Pending | 04-Apr-2024 | ||
| WO-2025038414-A1 | Therapeutic methods of use of gas bubble compositions | Inactive | 16-Aug-2023 | ||
| AU-2023217725-A1 | Gas nano/micro-bubble compositions and uses thereof | Inactive | 09-Feb-2022 | ||
| EP-4475899-A1 | Gas nano/micro-bubble compositions and uses thereof | Pending | 09-Feb-2022 | ||
| EP-4475899-A4 | Gas nano/micro-bubble compositions and uses thereof | Pending | 09-Feb-2022 | A61K49/223 |
Lantheus Holdings Signals
Lantheus Holdings Investments & Acquisitions (12)
Lantheus Holdings’s most recent deal was a PIPE with Radiopharm Theranostics for . The deal was made on 04-Dec-2025.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Radiopharm Theranostics | 04-Dec-2025 | PIPE | Drug Discovery | ||
| Life Molecular Imaging | 21-Jul-2025 | Merger/Acquisition | Other Pharmaceuticals and Biotechnology | ||
| Evergreen Theragnostics | 01-Apr-2025 | Merger/Acquisition | BPO/Outsource Services | ||
| Radiopharm Theranostics | 09-Jan-2025 | PIPE | Drug Discovery | ||
| Radiopharm Theranostics | 22-Dec-2024 | PIPE | Drug Discovery |
Lantheus Holdings ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
29.19 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,593
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Pharmaceuticals
Subindustry
of 354
Rank
Percentile
Lantheus Holdings Affiliates
Subsidiaries (7)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Evergreen Theragnostics | Springfield, NJ | 2019 | |
| Meilleur Technologies | Dublin, OH | 2018 | |
| Lantheus Cerveau | Bedford, MA | 2016 | |
| Life Molecular Imaging | Berlin, Germany | 2012 | |
| Lantheus Medical Imaging Retirement Savings Plan | North Billerica, MA | 2008 |
Lantheus Holdings FAQs
-
When was Lantheus Holdings founded?
Lantheus Holdings was founded in 1956.
-
Where is Lantheus Holdings headquartered?
Lantheus Holdings is headquartered in Bedford, MA.
-
What is the size of Lantheus Holdings?
Lantheus Holdings has 1,193 total employees.
-
What industry is Lantheus Holdings in?
Lantheus Holdings’s primary industry is Other Devices and Supplies.
-
Is Lantheus Holdings a private or public company?
Lantheus Holdings is a Public company.
-
What is Lantheus Holdings’s stock symbol?
The ticker symbol for Lantheus Holdings is LNTH.
-
What is the current stock price of Lantheus Holdings?
As of 20-Nov-2026 the stock price of Lantheus Holdings is $102.09.
-
What is the current market cap of Lantheus Holdings?
The current market capitalization of Lantheus Holdings is $6.68B.
-
What is Lantheus Holdings’s current revenue?
The trailing twelve month revenue for Lantheus Holdings is $1.56B.
-
Who are Lantheus Holdings’s competitors?
GE HealthCare Technologies, Guerbet Group, Bruker, Boston Scientific, and Bio-Rad Laboratories are some of the 8 competitors of Lantheus Holdings.
-
What is Lantheus Holdings’s annual earnings per share (EPS)?
Lantheus Holdings’s EPS for 12 months was $4.14.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process